Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting
While the introduction of combination highly active antiretroviral therapy (HAART) regimens represents an important advance in the management of human immunodeficiency virus (HIV)-infected patients, tolerability can be an issue and the use of several different agents may produce problems. The switch...
Main Authors: | Arribas, José R, Doroana, Manuela, Turner, Dan, Vandekerckhove, Linos, Streinu-Cercel, Adrian |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3610245/ |
Similar Items
-
Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens
by: López-Cortés, Luis F., et al.
Published: (2016) -
Neurocognitive impairment screening in Romanian HCV infected patients
by: Cercel, Ioana-Catrinel, et al.
Published: (2013) -
Exploring the role and function of trial steering committees: results of an expert panel meeting
by: Harman, Nicola L., et al.
Published: (2015) -
Computerized screening tools for neurocognitive impairment in patients with HIV infection
by: Cercel, Ioana-Catrinel, et al.
Published: (2014) -
Ritonavir-boosted protease inhibitor monotherapy is 6% less effective than combination antiretroviral therapy in a meta-analysis
by: Bierman, WFW, et al.
Published: (2010)